IP Library Granted Patent US 10,351,626
Granted Patent B2
US 10,351,626 · App. 14/774,647 · Granted Jul 16, 2019

Targeting agent antibody conjugates and uses thereof

Inventors: Chanhyuk Kim (San Diego, CA); Jun Y. Axup (San Diego, CA); Hwayoung Yun (San Diego, CA); Peter G. Schultz (La Jolla, CA); Jennifer Ma (La Jolla, CA); Jiayin Shen (San Diego, CA); Pengyu Yang (San Diego, CA)
Assignee: The Scripps Research Institute
C07K16/2809A61K39/3955A61K39/39558A61K47/542C07C275/16C07C275/24C07D249/04C07K16/2803C07K16/2806C07K16/2851C07K16/2863C07K16/2887C07K16/2896C07K16/3069C07K16/32C07K16/468A61K2039/505C07K2317/31C07K2317/33C07K2317/35C07K2317/52C07K2317/55C07K2317/56C07K2317/73C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,351,626
App. No.
14/774,647
Granted
Jul 16, 2019
Kind
B2
Abstract

Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response.

Claims (10)

1. A targeting agent-antibody conjugate comprising:

a compound of Formula XI:

and an antibody or antibody fragment that binds an antigen on a cytotoxic effector cell, wherein the wavy line of Formula XI indicates a point of attachment to the antibody or antibody fragment.

2. The targeting agent-antibody conjugate of claim 1 , wherein the antibody or antibody fragment comprises one or more unnatural amino acids.

3. The targeting agent-antibody conjugate of claim 1 , wherein the antigen is a CD3 T-cell co-receptor.

4. The targeting agent-antibody conjugate of claim 1 , wherein the antibody or antibody fragment comprises an anti-CD3 Fab.

5. The targeting agent-antibody conjugate of claim 2 , wherein the one or more unnatural amino acids of the antibody or antibody fragment comprises a p-acetylphenylalanine (pAcF) or a selenocysteine.

6. A pharmaceutical composition comprising the targeting agent-antibody conjugate of claim 1 .

7. A method for treating a cancer in a subject in need thereof, comprising administering an effective amount of the composition of claim 6 .

8. The method of claim 7 , wherein the cancer comprises a prostate cancer, an epithelial cancer, a kidney cancer, lung cancer, a colon cancer, a colorectal cancer, a gastric cancer, a brain cancer, a glioblastoma, a pancreatic cancer, a myeloid leukemia, a cervical cancer, a medullary thyroid carcinoma, a breast cancer, an ovarian cancer, an astrocytoma, an endometrial cancer, a neuroendocrine cancer, a gastroenteropancreatic tumor, a non-Hodgkin's lymphoma, an exocrine pancreatic cancer, an Ewing's sarcoma, or a skin cancer.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jul 6, 2016
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039265/0588 →
CONFIRMATORY LICENSE Recorded Nov 27, 2015
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037161/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2015
From: KIM, CHANHYUK; SCHULTZ, PETER G.; MA, JENNIFER; SHEN, JIAYIN
To: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH
Reel/Frame 036919/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2015
From: KIM, CHANHYUK; AXUP, JUN Y.; YUN, HWAYOUNG; SCHULTZ, PETER G.; YANG, PENGYU
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 036919/0454 →
Continuity (3)
Provisional Application 61839330 · Jun 25, 2013
Provisional Application 61783426 · Mar 14, 2013
Related Publication 20160115232A1 · Apr 28, 2016
Cited By (1)
US 12,252,534